A randomized controlled trial tested CannEpils effects on simulated driving performance and ocular (eye movement) activity to inform driving safety guidelines.
Medical cannabis patients, driving safety researchers, regulators, and prescribing physicians.
RCT on drivingControlled trial measured simulated driving impairment from standardized sublingual medical cannabis dose
What the researchers found
The study assessed the impact of a standardized sublingual dose of CannEpil (a THC-containing medical cannabis product) on simulated driving performance and ocular metrics, providing data to inform fitness-to-drive guidelines.
Why it matters
Medical cannabis patients need evidence-based guidance about when they can safely drive. This RCT provides specific data on a standardized product and dose to help develop driving safety policies.
The numbers in context
The study tested a standardized 1 mL sublingual dose of CannEpil, a medicinal cannabis product containing THC, using simulated driving and eye tracking assessments.
How the study worked
Randomized controlled trial measuring simulated driving performance and ocular activity following sublingual CannEpil administration.
Who was studied
Participants assessed for driving performance and eye movement after medical cannabis product administration.
What this study cannot tell us
Simulated driving may not fully represent real-world driving; single dose assessment; individual tolerance variation; specific product may not represent all medical cannabis formulations.
How to read the evidence
Randomized controlled trial with objective measurements; simulated rather than real-world driving.
When this study was published
Recent RCT addressing a pressing policy question for medical cannabis patients.
The bigger picture
This type of controlled driving study is essential for developing evidence-based fitness-to-drive guidelines that protect both medical cannabis patients and public safety.
Replication
Adds to small but growing body of controlled driving studies with medical cannabis; product-specific results may vary.
Funding
Not specified
Conflicts of interest
Not specified
Questions still open
- How long after the dose did driving impairment resolve?
- Could eye tracking serve as a roadside impairment test?
- Do regular medical cannabis users show less driving impairment?
Read the original research
Effect of CannEpil® on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial.
Journal of psychopharmacology (Oxford, England), 37(5), 472-483
Citation
Manning, Brooke; Hayley, Amie C; Catchlove, Sarah; Shiferaw, Brook; Stough, Con; Downey, Luke A. (2023). Effect of CannEpil® on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial.. Journal of psychopharmacology (Oxford, England), 37(5), 472-483. https://doi.org/10.1177/02698811231170360